Monopar Therapeutics Inc.
MNPR
$43.15
$1.333.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -85.50% | 31.73% | 28.26% | 27.49% | 20.10% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 199.98% | -26.45% | -7.05% | 8.20% | 15.63% |
| Change in Net Operating Assets | 357.70% | -1,625.89% | -449.08% | -175.08% | -182.27% |
| Cash from Operations | 18.51% | 21.84% | 12.85% | -2.99% | -8.71% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -390.98% | 200.31% | 166.88% | 183.50% | 200.19% |
| Cash from Investing | -390.98% | 200.31% | 166.88% | 183.50% | 200.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,763.59% | 91.61% | 138.39% | 377.47% | 1,795.98% |
| Repurchase of Common Stock | -121.96% | 30.56% | 46.31% | 46.88% | 38.85% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,824.84% | 90.56% | 140.44% | 415.54% | 6,080.49% |
| Foreign Exchange rate Adjustments | 102.98% | 92.82% | 95.36% | 43.38% | -380.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,289.79% | 105.74% | 88.16% | 117.22% | 92.41% |